Latest Breaking News On - Decheng - Page 1 : comparemela.com

850,000 Shares in Phathom Pharmaceuticals, Inc (NASDAQ:PHAT) Acquired by Decheng Capital LLC

850,000 Shares in Phathom Pharmaceuticals, Inc (NASDAQ:PHAT) Acquired by Decheng Capital LLC
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

United statesStifel nicolausMolly hendersonZurcher kantonalbank zurich cantonalbankTerrie curranDecheng capitalPrincipal financial group incInsider transactions at phathom pharmaceuticalsPhathom pharmaceuticals incNeedham companyPhathom pharmaceuticals company profileNews ratings for phathom pharmaceuticals dailyPhathom pharmaceuticalsChina universal asset management coQuarter for phathom pharmaceuticalsPhathom pharmaceuticals stock performance

27,429 Shares in argenx SE (NASDAQ:ARGX) Acquired by Decheng Capital LLC

27,429 Shares in argenx SE (NASDAQ:ARGX) Acquired by Decheng Capital LLC
modernreaders.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from modernreaders.com Daily Mail and Mail on Sunday newspapers.

United statesDecheng capitalExchange commissionWells fargo companyParkside financial bankInvestment advisersMorgan stanleyBenjaminf edwards company incPrincipal securities incFree reportFinancial bankPrincipal securitiesWells fargoStock downGet free reportMiddle east

Chinese biopharma firm IMPACT closes $55m Series D+ round to advance cancer drugs

The Series D+ round was led by GTJA Investment Group and Beijing-based state capital investor Kingray Capital.

Leiwen chenJunshi biosciencesNational medical products administrationYangzhou guojin groupInvestment groupDrug administrationYangzhou cityLilly asia venturesNew drug applicationKingray capitalEikon therapeuticsHong kong listedWuxi apptecCenova venturesDecheng capital

Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction

Acquisition transforms Nuvation Bio into late-stage global oncology company with potential to become a commercial organization by the end of 2025 Acquisition adds taletrectinib, a next-generation,.

United statesNew yorkSan franciscoCayman islandsDaiichi sankyoJunyuan jerry wangInnovent biologicsNuvation bioWalkers caymanMorrison foerster llpExchange commissionMorrison foersterDrug administrationChina national medical products administrationDavis polk wardwellAnheart therapeutics ltd

Nuvation Bio Inc entered into an Agreement and Plan of Merger to acquire AnHeart Therapeutics Ltd

Nuvation Bio Inc. entered into an Agreement and Plan of Merger to acquire AnHeart Therapeutics Ltd. on March 24, 2024. Nuvation Bio entered into a definitive agreement for Nuvation Bio to acquire.

Cayman islandsUnited statesLee hochbaumJunyuan jerry wangNuvation bioYasin keshvargarMorrison foersterMorrison foerster llpDavis polk wardwellNuvation bio incAnheart therapeutics ltdWalkers caymanAnheart therapeuticsNon voting convertible preferred stockNuvation bio stockholder approvalNuvation bio stockholder